Nuvalent, Inc. 4

Chief Technical Operations Officer Benjamin Lane tendered 21,092 Nuvalent Class A shares and had all RSUs, PSUs, and stock options on roughly 110,000+ underlying shares cashed out at the $124.00 merger price, leaving him with no remaining equity holdings.

On July 15, 2026, in connection with the closing of GlaxoSmithKline’s acquisition of Nuvalent, Inc. at $124.00 per share, Chief Technical Operations Officer Benjamin Lane had 21,092 shares of Nuvalent Class A Common Stock converted into cash in the tender offer, and all of his equity awards were cash-settled and cancelled pursuant to the Merger Agreement. This included the cancellation of 29,433 time-based Class A Common Stock RSUs and 7,120 performance stock units (PSUs), each converted into cash at the $124.00 offer price, as well as the vesting and cash‑out of 7,120 PSUs that became earned at closing. In addition, multiple outstanding stock options (with exercise prices ranging from $14.40 to $106.82) covering 73,797 underlying shares in aggregate were cancelled and converted into cash equal to the intrinsic value based on the $124.00 offer price. Following these transactions, Lane reported zero direct ownership of Nuvalent equity securities, as the company became a wholly owned subsidiary of GlaxoSmithKline LLC.

Filing Facts

CIK

1861560

Ticker

NUVL

Form

4

Source Type

fda

Accession

0001193125-26-305068

Alert Tier

6